Bedrijfsvoering Amgen Inc.

AMGN

US0311621009

Farmaceutische producten

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 16-01-2026			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
330,41 ^USD	+0,12%		+1,32%	+0,95%

15/01	Espiria Hållbar Framtid steeg in december met 0,4 procent - verhoogd belang in Epiroc en Afry	FW
14/01	Honeywell meldt dat Quantinuum vertrouwelijke indiening van IPO-ontwerpregistratie plant	MT

Uitvoerend comité: Amgen Inc.

Bedrijfsleider

Beklede functiesVan

Robert Bradway

63 jaar

Chief Executive Officer	01-05-2012
President	01-05-2010

Scott Skellenger

Chief Tech/Sci/R&D Officer

01-10-2022

Howard Y. Chang

Chief Tech/Sci/R&D Officer

16-12-2024

Paul Burton

57 jaar

Chief Tech/Sci/R&D Officer

01-06-2023

James Bradner

53 jaar

Chief Tech/Sci/R&D Officer

18-12-2023

Matthew Busch

52 jaar

Comptroller/Controller/Auditor

14-08-2023

Derek Miller

53 jaar

Human Resources Officer

01-09-2004

Mark J. Taisey

General Counsel

01-01-2014

Nancy Grygiel

58 jaar

Compliance Officer

01-01-2016

Peter Griffith

67 jaar

Director of Finance/CFO

01-01-2020

Esteban Santos

59 jaar

Chief Operating Officer

25-07-2016

Jonathan Graham

65 jaar

General Counsel	13-07-2015
Corporate Secretary	13-07-2015

David Reese

63 jaar

Chief Tech/Sci/R&D Officer

26-07-2018

Samenstelling van de raad van bestuur: Amgen Inc.

Directeur

RadenVan

Robert Bradway

63 jaar

Executive Committee Chair	01-01-2013
Governance Committee	14-10-2016
Finance Committee Chair

Robert Eckert

71 jaar

Compensation Committee	26-03-2021
HR Committee	26-03-2021
Governance Committee Chair	26-03-2021
Nominating Committee Chair	26-03-2021
Executive Committee	01-01-2012
Governance Committee	20-03-2020
Nominating Committee	20-03-2020
Compensation Committee Chair

Greg Garland

68 jaar

Executive Committee
Compensation Committee	16-10-2013
Governance Committee Chair
Nominating Committee Chair
Audit Committee	03-11-2025
Finance Committee	03-11-2025

Charles Holley

69 jaar

Executive Committee	03-02-2017
Governance Committee
Nominating Committee	03-02-2017
Audit Committee Chair	01-04-2020
Audit Committee	04-10-2019
Finance Committee	04-10-2019

Wanda Austin

71 jaar

Compensation Committee	24-10-2017
Governance Committee Chair	01-12-2016
Nominating Committee Chair	01-12-2016
Audit Committee
Finance Committee

Amy Miles

59 jaar

Governance Committee	15-01-2025
Audit Committee Chair
Finance Committee Chair	01-04-2020
Audit Committee	15-01-2025
Nominating Committee	23-07-2020

Ellen Kullman

70 jaar

Governance Committee Chair	08-05-2023
Nominating Committee Chair	08-05-2023
Governance Committee	21-12-2016
Nominating Committee	21-12-2016
Compensation Committee	21-12-2016

Omar Ishrak

71 jaar

Audit Committee	01-08-2023
Compensation Committee	30-07-2021
Governance Committee	01-08-2023
Nominating Committee	01-08-2023

Mary Klotman

71 jaar

Governance Committee	31-05-2024
Nominating Committee	11-11-2022
Compensation Committee	11-11-2022

Tyler Jacks

65 jaar

Finance Committee	24-02-2015
Compensation Committee

Michael Drake

75 jaar

Governance Committee	03-08-2022
Nominating Committee	03-08-2022

Brian Druker

70 jaar

Compensation Committee

23-05-2018

Recente benoemingen: Amgen Inc.

13/01	Aligos Therapeutics, Inc. benoemt James Hassard tot Executive Vice President en Chief Commercial Officer, met ingang van 13 januari 2026	CI
12/01	BioMarin Pharmaceutical benoemt Arpit Dave tot Chief Digital and Information Officer	MT
12/01	BioMarin Pharmaceutical Inc. benoemt Arpit Davé tot Executive Vice President en Chief Digital and Information Officer	CI
12/01	Spyre Therapeutics, Inc. benoemt Kate Tansey Chevlen tot Chief Commercial Officer	CI
08/01	Praxis Precision Medicines, Inc. kondigt wijzigingen in het management aan	CI
07/01	SAB Biotherapeutics, Inc. kondigt wijzigingen in Raad van Bestuur aan, met ingang van 7 januari 2026	CI
07/01	Viking Therapeutics, Inc. kondigt benoeming van Neil Aubuchon aan als Chief Commercial Officer	CI

Meer nieuws

Voormalige zaakvoerders en bestuurders: Amgen Inc.

Insider

Beklede functies

VanTot

Frank Herringer

Director/Board Member	01-05-2004	22-05-2019
Independent Dir/Board Member	22-04-2011	22-05-2019

David Baltimore

Director/Board Member	01-01-1997	22-05-2018
Independent Dir/Board Member	22-04-2011	22-05-2018

Frank J. Biondi

Director/Board Member	01-01-2002	19-05-2017
Independent Dir/Board Member	22-04-2011	19-05-2017

Judith C. Pelham

Director/Board Member	01-05-1995	19-05-2017
Independent Dir/Board Member	22-04-2011	19-05-2017

Rolf K. Hoffmann

Corporate Officer/Principal

01-11-2004

01-07-2016

Vance D. Coffman

Director/Board Member	02-10-2007	01-01-2016
Independent Dir/Board Member	22-04-2011	01-01-2016

Willard Dere

Chief Tech/Sci/R&D Officer	01-06-2007	01-10-2014
Corporate Officer/Principal	01-06-2007	01-06-2007

Joseph P. Miletich

Chief Tech/Sci/R&D Officer

01-04-2002

01-07-2014

Gilbert Omenn

Director/Board Member	01-01-1987	15-05-2014
Independent Dir/Board Member	22-04-2011	15-05-2014

Leonard Schaeffer

Director/Board Member	01-03-2004	08-07-2013
Independent Dir/Board Member	22-04-2011	08-07-2013

J. Reason

Director/Board Member	01-01-2001	22-05-2013
Independent Dir/Board Member	22-04-2011	22-05-2013

Fabrizio Bonanni

Chief Operating Officer

01-04-1999

01-01-2013

David Beier

Public Communications Contact	19-04-2011	08-10-2012
General Counsel	01-12-2003	08-10-2012
Corporate Officer/Principal	08-10-2012	01-01-2013

Kevin Sharer

Chief Executive Officer	01-01-2000	01-05-2012
Chairman	01-10-1992	31-12-2012
President	01-10-1992	01-01-2000

Roger Perlmutter

Chief Tech/Sci/R&D Officer

01-01-2001

12-02-2012

Roy Baynes

Corporate Officer/Principal

01-08-2002

01-01-2012

Frederick Gluck

Director/Board Member	01-02-1998	01-10-2011
Independent Dir/Board Member	22-04-2011	01-10-2011

Lisa Guttman

Corporate Officer/Principal

01-01-2000

01-10-2007

Richard Nanula

Director of Finance/CFO

01-08-2001

10-04-2007

Donald B. Rice

Director/Board Member

01-10-2000

17-01-2007

Lisa A. Evrén

Treasurer

01-01-2002

01-01-2007

Hassan A. Dayem

Chief Tech/Sci/R&D Officer

01-05-2002

20-09-2006

Timothy Martin

Comptroller/Controller/Auditor	01-08-2003	01-05-2006
Director of Finance/CFO	01-08-2003	01-05-2006

David Parkinson

Corporate Officer/Principal

01-05-2003

01-03-2006

Keith L. Klein

General Counsel

01-01-1991

01-01-2006

Edward V. Fritzky

Director/Board Member

01-07-2002

01-05-2005

Charles R. Bradley

Corporate Officer/Principal

01-01-2000

01-01-2005

Michael Narachi

Corporate Officer/Principal

01-07-1984

01-01-2003

Thomas James Flanagan

Chief Tech/Sci/R&D Officer

01-06-2004

Steve Lazarus

Director/Board Member

01-05-1987

13-05-2004

Patricia Cary Sueltz

Director/Board Member	08-01-2002	01-05-2004
Independent Dir/Board Member	08-01-2002	01-05-2004

David J. Scott

General Counsel	01-03-2004	-
Corporate Secretary	01-03-2004	-

Kevin B. Young

Corporate Officer/Principal

01-01-2001

01-01-2004

Joseph J. Tsiakals

Corporate Officer/Principal

01-01-2000

01-01-2004

Martha E. Vincent

Chief Tech/Sci/R&D Officer

01-01-1995

01-01-2004

Bradley J. Maroni

Corporate Officer/Principal

01-01-1998

01-01-2004

Wen-Tse Tseng

Corporate Officer/Principal

10-09-1998

10-09-2003

Diane M. Palumbo

Human Resources Officer

01-06-1991

01-07-2003

Carl LeBel

Corporate Officer/Principal

01-01-1993

David Hallal

Sales & Marketing

01-01-1992

01-08-2002

Nicholas Lydon

Corporate Officer/Principal

01-12-2000

02-01-2002

Robin D. Campbell

Corporate Officer/Principal

01-01-1989

01-01-2002

Brian M. McNamee

Human Resources Officer	01-06-2001	07-11-2013
Corporate Officer/Principal	07-11-2013	-

Matthew Moyle

Corporate Officer/Principal

01-01-1995

01-01-2001

Gordon Binder

Chief Executive Officer

01-01-1982

01-01-2000

Henry Wu

Corporate Officer/Principal

01-01-1999

Denny Lanfear

Corporate Officer/Principal

01-01-1986

01-01-1999

Gisela Schwab

Chief Tech/Sci/R&D Officer

01-01-1992

Jerry D. Choate

Director/Board Member	01-08-1998	-
Independent Dir/Board Member	22-04-2011	-

Julia Eastland

Comptroller/Controller/Auditor

01-03-1996

01-04-1998

Margaret E. Valeur-Jensen

Corporate Officer/Principal

01-01-1991

01-01-1998

Rosemary Mazanet

Chief Tech/Sci/R&D Officer

01-01-1993

01-01-1998

Danute M. Bankaitis-Davis

Chief Tech/Sci/R&D Officer

01-01-1992

01-01-1998

Kathleen M. Wiltsey

Sales & Marketing

01-01-1984

01-01-1998

Gregory Stea

Sales & Marketing

01-05-1988

01-01-1997

Peter García

Corporate Officer/Principal

01-01-1990

Richard Yeh

Corporate Officer/Principal

01-10-1995

Mark Moon

Corporate Officer/Principal

01-01-1989

02-01-1995

Lowell Sears

Director of Finance/CFO

01-01-1986

01-01-1994

Alan B. Forsythe

Corporate Officer/Principal

01-01-1991

G. Kirk Raab

Director/Board Member

01-01-1981

01-01-1985

Elaine Richardson

Corporate Officer/Principal

Alexander Lopez

Corporate Officer/Principal

Ralph Niven

Corporate Officer/Principal

Edward H. Shin

Corporate Officer/Principal

Jeffrey D. Webster

Corporate Officer/Principal

Ernest Allen

Corporate Officer/Principal

Joshua Disbrow

Corporate Officer/Principal

M. Patricia Beckmann

Corporate Officer/Principal

Kathleen Stafford

Treasurer

John Shutter

Public Communications Contact

David Polk

Public Communications Contact

Steve Bandler

Corporate Officer/Principal

Steven R. Wiley

Corporate Officer/Principal

Bertrand C. Liang

Corporate Officer/Principal

James H. Chamberlain

Corporate Officer/Principal

Nancy Stuart

Corporate Officer/Principal

Alec Green

Corporate Officer/Principal

Sanjay Kanungo

Corporate Officer/Principal

Howard J. Lewin

Corporate Officer/Principal

Luc Marengère

Corporate Officer/Principal

Leeftijdsdistributie van bedrijfsleiders

Ratio vrouwen/mannen

Man	25
Vrouw	6

Waarvan leden van het uitvoerend comité

Man	12
Vrouw	1

Waarvan bestuurders

Man	10
Vrouw	2

Herzieningen

Révisions CA 1 an

Révisions CA 4 mois

Révisions CA 1 mois

Révisions BNA 1 an

Révisions BNA 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Nee

Controverses sur les droits de l'Homme

Nee

Controverses Subventions fiscales

Conforme à la finance Islamique

Nee

Amgen Inc. is wereldwijd een van de grootste concerns voor biotechnologie. De omzet per inkomstenbron wordt als volgt onderverdeeld: - verkoop van medicijnen (95,8%): medicijnen bestemd voor de behandeling van kanker, problemen met de stofwisseling, botziektes, nierfalen, hemofilie, enz.; - overige (4,2%): met name royalty's. 71,4% van de omzet wordt gemaakt in de Verenigde Staten.

Werknemers

28.000

Sector

Farmaceutische producten

Agenda

03/02 - Q4 2025 Cijferpublicaties

Meer informatie over het bedrijf